Loading
The study that showed one CAR-T infusion could keep a third of heavily pretreated myeloma patients progression-free for five years without further treatment.
CARTITUDE-1, trial NCT03548207 sponsored by Janssen and Legend and reported in 2021, was the study that showed one CAR-T infusion of ciltacabtagene autoleucel could keep a third of heavily pretreated, triple-class-exposed myeloma patients progression-free for five years without further treatment. In 97 patients after at least three prior lines the response rate was 98 percent with stringent complete responses in 83 percent, and the five-year JCO update in 2025 found a third still progression-free with no maintenance and sustained MRD negativity in most, while movement disorders occurred in about five percent of the early cohort. OnCo links it to multiple myeloma, CAR-T, cilta-cel, Fangliang Zhang, Jesús G. Berdeja, the LEGEND-2 trial and the CARTITUDE-1 paper. Whether those long-term remissions represent cures is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
One of the most cited trial reports Europe PMC returns for Ciltacabtagene autoleucel in Multiple myeloma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
CARTITUDE-1 showed that a single CAR-T infusion can put late-stage myeloma into deep, multi-year remission, leading to FDA approval of cilta-cel in 2022 for heavily pretreated disease. It set the efficacy bar for BCMA-directed therapy and motivated moving CAR-T earlier (CARTITUDE-4). Late neurological toxicity and secondary malignancies remain the safety questions.
Shares Legend Biotech, LEGEND-2, Ciltacabtagene autoleucel, Relapsed or refractory multiple myeloma.
Shares Legend Biotech, CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma, Ciltacabtagene autoleucel, Relapsed or refractory multiple myeloma.
Shares Ciltacabtagene autoleucel, Johnson & Johnson, CAR-T cell therapy, Multiple myeloma.
Shares Ciltacabtagene autoleucel, Johnson & Johnson, CAR-T cell therapy, Multiple myeloma.
Shares FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma, Ciltacabtagene autoleucel, CAR-T cell therapy, Multiple myeloma.
Shares Legend Biotech, Ciltacabtagene autoleucel, Johnson & Johnson, CAR-T cell therapy.
Shares Jesús G. Berdeja, Multiple myeloma.
Shares Ciltacabtagene autoleucel, Johnson & Johnson, CAR-T cell therapy, Multiple myeloma.